HitGen Inc. announced that it has entered into a research service agreement with Nested Therapeutics Inc. under which HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify hits against targets of interest to HitGen. HitGen is a world leader in the development of DEL technology and applications to early-stage small molecule drug discovery. Its platform includes over 1.2 trillion small molecules generated by the DEL technology and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organizations around the world.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.52 CNY | +1.27% | +16.45% | -9.81% |
Apr. 24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.81% | 746M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- 688222 Stock
- News HitGen Inc.
- HitGen Inc. Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics, Inc